Evidence map›Paper›PMID 26500848›Full record

ArticleLeukemia research reports2015

A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.

Jeffrey V Leyton, Catherine Gao, Brent Williams, Armand Keating, Mark Minden, Raymond M Reilly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Development of [Leukemia · 2022
    Article
  7. Article
  8. Review
  9. New physical approaches to treat cancer stem cells: a review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jeffrey V LeytonDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Catherine GaoDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
Brent WilliamsInstitute of Medical Science, University of Toronto, Toronto, ON, Canada ; Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, ON, Canada ; Cell Therapy Program, The Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Armand KeatingCell Therapy Program, The Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada ; Department of Hematology-Oncology, The Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mark MindenDepartment of Hematology-Oncology, The Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada ; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Raymond M ReillyDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada ; Toronto General Research Institute, University Health Network, Toronto, ON, Canada ; Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada.
University of Toronto · CAHospital for Sick Children · CAPrincess Margaret Cancer Centre · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioimmunotherapy (RIT) with anti-CD123 monoclonal antibody CSL360 modified with nuclear translocation sequence (NLS) peptides and labeled with the Auger electron-emitter, (111)In ((111)In-NLS-CSL360) was studied in the prevalent NOD/SCID mouse AML engraftment assay. Significant decreases in CD123(+) leukemic cells and impairment of leukemic stem cell self-renewal were achieved with high doses of RIT. However, NOD/SCID mice were very radiosensitive to these doses. At low non-toxic treatment doses, (111)In-NLS-CSL360 demonstrated a trend towards improved survival associated with decreased spleen/body weight ratio, an indicator of leukemia burden, and almost complete eradication of leukemia from the bone marrow in some mice.

Indexed as

111InAMLAuger electronsLeukemia stem cellsMonoclonal antibodies

Identifiers

PMID26500848
PMCPMC4588397
OpenAlexW2168088054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.